Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech
Update: 2025-10-06
Description
Melanie Whittington, Head of the Leerink Center for Pharmacoeconomics, interviews Steve Potts, PhD, MBA, CEO and Co-Founder, Stealth Cancer Biotech, to discuss the impact of the Inflation Reduction Act on cancer drug development and a middle ground between a market-based approach and a government-based approach to drug pricing.
Comments
In Channel














